← Back to Search

Unknown

STP1002 for Solid Tumors

Phase 1
Waitlist Available
Research Sponsored by ST Pharm Co., Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 months
Awards & highlights

Study Summary

This trialtests a new drug to find the safest dose for cancer patients.

Eligible Conditions
  • Advanced Solid Tumors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Dose limiting toxicities (DLTs)
Secondary outcome measures
The pharmacokinetics of STP1002
Treatment-emergent adverse events (TEAEs)

Trial Design

1Treatment groups
Experimental Treatment
Group I: STP1002Experimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
STP1002
2020
Completed Phase 1
~40

Find a Location

Who is running the clinical trial?

ST Pharm Co., Ltd.Lead Sponsor
1 Previous Clinical Trials
36 Total Patients Enrolled
KCRN Research, LLCIndustry Sponsor
8 Previous Clinical Trials
417 Total Patients Enrolled

Media Library

STP1002 (Unknown) Clinical Trial Eligibility Overview. Trial Name: NCT04505839 — Phase 1
Solid Tumors Research Study Groups: STP1002
Solid Tumors Clinical Trial 2023: STP1002 Highlights & Side Effects. Trial Name: NCT04505839 — Phase 1
STP1002 (Unknown) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04505839 — Phase 1
~7 spots leftby Jun 2025